Electrically driven contractions reliably add lean tissue and maximal strength in non-athletes, with strength gains roughly matching weight training when volume is matched, and the largest gains in sedentary, immobilised, or ageing adults. It loads neither bone nor tendon. The trade-off is muscle damage: a first full-intensity session can cause severe muscle breakdown, so the opening weeks carry the hazard. (Full Review)

Protocol

Standard whole-body regimen

20 min, 85 Hz, 350 µs

Bipolar current, intermittent 6 s stimulation to 4 s rest, at moderate-to-high perceived intensity while performing low-load dynamic movements

Session frequency

1 session per week

Tested standard for whole-body application; 1.5 weekly in sarcopenic obesity; three per fortnight sufficed in women aged around 75

Intensity threshold

Above ~50% of maximal voluntary contraction

The parameter that determines whether anything happens; effective protocols averaged 63%

Time to effect

Muscle size

8 weeks

Cross-sectional area changes absent at 4 weeks, present at 8

Maximal strength

4 weeks

Strength changes appear first, and enlarge by 8 weeks

Whole-body lean mass

12–16 weeks

Scan-measured; perceived change is unreliable over this period

Benefits

High: Skeletal muscle mass and size gains; maximal strength gains; power and explosive performance gains; functional capacity in older and deconditioned adults

Medium: Preservation of muscle during enforced inactivity; retention of lean mass during energy restriction

Low: Reduction in body fat and waist circumference; added effect when superimposed on voluntary contraction

Speculative: Myokine and metabolic signalling

Contraindications

Implanted pacemaker, cardioverter-defibrillator, neurostimulator, insulin pump or other active implant

Pregnancy, at any stage

Epilepsy and other neurological or neuronal disorders

Arteriosclerosis and peripheral arterial circulation disorders

Chronic kidney disease stage 4 or worse (eGFR below 30 mL/min/1.73 m²)

Documented rhabdomyolysis within the prior 3 months, or creatine kinase above 5 times the upper reference limit

Acute febrile illness, acute infection, or acute deep vein thrombosis

Untreated or uncontrolled hypertension above 160/100 mmHg

Abdominal or inguinal hernia; surgical wounds or implants beneath the electrode field within 8 weeks

Active malignancy under treatment, and diabetes mellitus with peripheral neuropathy (relative; medical clearance required)

Key Interactions

Statins and fibrates (atorvastatin, rosuvastatin, simvastatin, fenofibrate)

Loop and thiazide diuretics (furosemide, hydrochlorothiazide)

Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac gel)

Antipsychotics and serotonergic agents (haloperidol, olanzapine, fluoxetine)

Creatine monohydrate (monitor)

Protein and leucine supplementation (no caution required)

Caffeine-based pre-workout formulas and other stimulant supplements

Heavy eccentric resistance training (same muscles within 48–72 hours)

Sauna, heat exposure and fasted training

Risk & Side Effects

High: Exertional muscle damage and rhabdomyolysis; skin irritation and electrode-site reactions

Medium: Cardiac biomarker elevation

Low: Pain-limited and subjectively dosed intensity; interference with implanted cardiac devices

Speculative: Transient immune and inflammatory perturbation

Monitoring

Marker	Target	Why
Creatine kinase (CK)	50–200 IU/L at rest; below 1,000 IU/L at 72 h post-session	Direct index of muscle fibre damage
Serum creatinine and estimated glomerular filtration rate (eGFR)	eGFR above 90 mL/min/1.73 m²; creatinine in lower half of reference range	Kidney filtration is the organ at risk when myoglobin is released
Urine dipstick for blood, with microscopy	Negative for blood	Dipstick-positive blood with no red cells on microscopy indicates myoglobin, the step before kidney injury
Serum potassium	4.0–4.5 mmol/L	Damaged fibres release potassium; sharp rises affect heart rhythm
High-sensitivity troponin T (hsTnT)	Below the assay’s 99th-percentile limit	Distinguishes heart-muscle involvement from skeletal spillover when enzymes are very high
High-sensitivity C-reactive protein (hsCRP)	Below 1.0 mg/L	General inflammatory load; guides whether recovery is keeping pace
Appendicular skeletal muscle mass index (ASMI) by scan	Above 7.0 kg/m² men, above 5.5 kg/m² women	The primary outcome — muscle actually gained
Handgrip strength	Above 27 kg men, above 16 kg women; rising from own baseline	Cheap, repeatable proxy for whole-body strength gain
Serum 25-hydroxyvitamin D	40–60 ng/mL	Deficiency independently impairs muscle function and raises damage susceptibility
Testosterone, total and free	Upper half of age-adjusted reference range	Sets the ceiling on hypertrophic response to any stimulus

Cadence: Creatine kinase 72 hours after the first session and again after the third, then only if symptoms recur; kidney filtration at baseline and 12 weeks; body composition with strength testing at baseline, 12 weeks and every 6 months after

Qualitative Assessment

Severity and duration of delayed muscle soreness, which should fall session over session as adaptation develops
Urine colour in the 72 hours after each of the first three sessions
Perceived exertion reached during the session, on a 10-point scale, as the only practical dosing feedback
Ability to complete normal daily activity and training the day after a session
Subjective muscle fullness and clothing fit, which change before scan-measurable mass does
Sleep quality in the nights following early sessions

Electrical Muscle Stimulation for Muscle Growth

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment